Press Releases

Photys Therapeutics, Inc. (“Photys”), a proximity-based therapeutics company, and Polymed Biopharmaceuticals, Inc. (“Polymed”), a global biotech company focused on creating best-in-class PROTACs (proteolysis targeting chimera) and DACs (degrader antibody conjugates) therapeutics, today announced the initiation of a Phase I clinical trial evaluating PHT-776/HPB-143, an investigational IRAK4 PROTAC candidate. PHT-776/HPB-143 is an oral IRAK4-targeted PROTAC des

Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). This marks the

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, today announced the signing of a Memorandum of Understanding (MoU) with Alfresa Holdings Corporation, one of Japan’s leading healthcare and pharmaceutical distribution groups, to establish a strategic collaboration for the development and future distribution of its lead product candidate ProtheraCytes® in Japan. The agreement follows the recent publication of the EXCELLENT clinical trial

University of Queensland researchers will accelerate life-changing health research after securing $29 million from the National Health and Medical Research Council (NHMRC).  The funding will support researchers at all career stages to establish innovative programs tackling major health challenges, including cancer, chronic disease, chronic pain, schizophrenia and fetal alcohol spectrum disorder (FASD).   The NHMRC Investigator Grants scheme allows recipients to f

Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the dosing of the first patient in the VIRAGE2 Phase 2a clinical trial, a small proof-of-concept study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic PDAC patients treated with standard-of-care gemcitabine/nab-paclitaxel chemotherapy (SoC;

The Foundation for Angelman Syndrome Therapeutics (FAST), the leading patient advocacy organization working to support the development of transformative treatment options for Angelman syndrome, today announced that it has entered into an agreement with Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines. Under the agreement, FAST may access TfR1 CapX™, Apertura's blood-brain barrier-crossing capsid technology, in inv

Alphamab Oncology (stock code: 9966.HK) today announced that the New Drug Application (NDA) for Anbenitamab (brand name: 恩尼妥®, KN026), a HER2 bispecific antibody independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with CSPC’s Docetaxel for Injection (Albumin-bound) (HB1801), for the neoadjuvant treatment of early or locally advanced HER

Sanofi has received European Commission (EC) approval to extend the indication of its MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age. The vaccine is approved to help protect against invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W and Y. MenQuadfi was previously authorised in the European Union for people aged 12 months and older. The approval follows a positive opinion from the Committee for Med

Verista, a leading provider of automation, compliance, and quality solutions for the life sciences industry, announced the acquisition of Integral Solutions. Based in Columbus, OH, Integral Solutions is a life sciences business and technology services firm that specializes in engineering and validation services worldwide. The acquisition enhances Verista’s capabilities in automation, engineering, project management, and validation, enabling the company to deliver further comprehensive s

Schrödinger, Inc. (Nasdaq: SDGR) today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist that helps researchers understand scientific objectives, develop computational strategies, execute sophisticated molecular discovery workflows and interpret results. By combining AI with physics-based simulation, Bunsen allows researchers to apply their expertise at greater scale, enabling them to explore more scientific possibilities, prioritize the most pro